Junshi Biosciences (01877) announced that the company recently received a Drug Supplementary Application Approval Notice issued by the National Medical Products Administration (NMPA), approving the indication of toripalimab injection (trade name: TUOYI®, product code: JS001) as a monotherapy for patients with locally advanced or metastatic urothelial carcinoma who have failed platinum-containing chemotherapy, including disease progression within 12 months of neoadjuvant or adjuvant chemotherapy. The approval has been converted from conditional approval to full approval.